Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Rimegepant for Migraine Prevention in Japanese Adults
jRCT2031220237Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Rimegepant arm with Placebo arm (2 arms). Primary endpoint: Primary efficacy endpoint. Started Aug 2022; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on jRCT2031220237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220237.